Display options
Cite
Nalli M, Puxeddu M, La Regina G, et al. Emerging Therapeutic Agents for Colorectal Cancer. Molecules. 2021;26(24)doi: 10.3390/molecules26247463.
Nalli, M., Puxeddu, M., La Regina, G., Gianni, S., & Silvestri, R. (2021). Emerging Therapeutic Agents for Colorectal Cancer. Molecules (Basel, Switzerland), 26(24), . https://doi.org/10.3390/molecules26247463
Nalli, Marianna, et al. "Emerging Therapeutic Agents for Colorectal Cancer." Molecules (Basel, Switzerland) vol. 26,24 (2021). doi: https://doi.org/10.3390/molecules26247463
Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules. 2021 Dec 09;26(24). doi: 10.3390/molecules26247463. PMID: 34946546.
Copy Download .nbib Format: NLM
Share it on

Molecules. 2021 Dec 09;26(24). doi: 10.3390/molecules26247463.

Emerging Therapeutic Agents for Colorectal Cancer.

Molecules (Basel, Switzerland)

Marianna Nalli, Michela Puxeddu, Giuseppe La Regina, Stefano Gianni, Romano Silvestri

Affiliations

  1. Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy.
  2. Department of Biochemical Sciences "Rossi Fanelli", Institute of Biology and Molecular Pathology of CNR, Sapienza University of Rome, 00185 Rome, Italy.

PMID: 34946546 DOI: 10.3390/molecules26247463

Abstract

There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC's therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.

Keywords: CRC; anticancer agents; cancer; emerging targets

Publication Types

Grant support